Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ESSA Pharma Inc
EPIX
Healthcare
Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen...
treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:EPIX)
New Post
View:
Posts & Comments
Threaded Posts
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 04, 2024 12:31pm
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pha
Breaking News: $EPIX Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Investors to ConnectNEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein
...more
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 03, 2024 10:15am
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pha
News; $EPIX Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to ConnectNEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 01, 2024 5:15pm
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz &
BREAKING NEWS: $EPIX ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationNEW YORK CITY, NY
...more
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 11, 2024 4:15pm
ESSA Pharma to Present at the 2024 Cantor Global Healthcare
BREAKING NEWS: $EPIX ESSA Pharma to Present at the 2024 Cantor Global Healthcare ConferenceESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 26, 2022 2:25pm
EPIX ..... I have to laugh at myself ; )
Funny how my emotions come back to haunt me ...... I made a $1 per share profit but I left about $2 on the table.....ya just never know how high the share price will go This really surpassed my
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 26, 2022 10:33am
EPIX ..... Yeeeehaaaaa !
Now Over $3...... Cha f'king Ching !!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 26, 2022 9:25am
EPIX ....On watch list
Relative volume and NR.....$2.07
(14)
•••
allison5120
X
View Profile
View Bullboard History
Post by
allison5120
on Oct 24, 2021 6:10pm
ESSA has begun recruiting for its phase 1/2 combo trial
ESSA has filed an update on clinicaltrials.gov announcing that it has begun recruiting patients for its phase 1/2 combination trial (EPI-7386 and Astellas/Pfizer's Enzalutimide). This is
...more
(1)
•••
SilentRiver
X
View Profile
View Bullboard History
Post by
SilentRiver
on Nov 25, 2020 9:15am
Evercore SII 3rd Annual HealthCONx Conference
ESSA Pharma to Participate at Evercore SII 3rd Annual HealthCONx Conference HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /CNW/ - ESSA Pharma
...more
(1)
•••
SilentRiver
X
View Profile
View Bullboard History
Post by
SilentRiver
on Nov 11, 2020 6:33am
Upcoming Investor Conferences
ESSA Pharma to Participate in Upcoming Investor Conferences HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /CNW/ - ESSA Pharma Inc.
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >